ClinicalTrials.gg
CompletedNCT02910063Updated Jan 13, 2021Results posted

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

A Phase 2/3 interventional study of Blinatumomab in B-Cell Non Hodgkin Lymphoma, sponsored by Amgen. Completed at 31 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-13.

Sponsored by Amgen · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Lymphoma, B-Cell with a site in Italy — 15 open to participants now, 32 under way, 9 of them phase 3. Lymphoma, B-Cell · Italy.

Enrollment
44th of 53
41 · median 154
Started
2017
with 1 other
Phase 2/3
Only one
of the 65
Registered
22nd of 65
by date

Among the 65 studies in Lymphoma, B-Cell with a site in Italy, this one is the 44th largest by enrollment of the 53 interventional ones that give a count, is one of 2 that started in 2017, is the only one in phase 2/3, and was the 22nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

15 of the 65 studies in Lymphoma, B-Cell with a site in Italy are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Lymphoma, B-Cell with a site in Italy, or all of them as a file.
02

Study summary

This is a phase 2/3 open label, multicenter trial testing blinatumomab monotherapy for the treatment of subjects with Relapsed/Refractory (R/R) aggressive B-NHL not achieving CMR after 2 cycles of standard platinum-based chemotherapy regimens administered as S1. This study incorporates multiple interim analyses for futility, efficacy, and unblinded sample-size re-estimation. In the phase 3 part of the study, blinatumomab will be compared to Investigator's Choice chemotherapy.

In March 2019, decision made to not proceed with phase 3.

Read the detailed description

This is a phase 2/3 open label, multicenter trial testing blinatumomab monotherapy for the treatment of subjects with R/R aggressive B-NHL not achieving CMR after standard platinum-based chemotherapy regimens administered as S1. This study incorporates multiple interim analyses for futility, efficacy, and unblinded sample-size re-estimation. In the phase 3 part of the study, blinatumomab will be compared to IC chemotherapy.The phase 2 component of the study will consist of up to a 28-day screening period, approximately 70 to 112 days of study treatment, a 30-day (+/- 3days) safety follow up, and long-term follow up that will conclude with the final analysis of the phase 3 component, estimated at 30 months after initiation of the phase 3 component. For the phase 3 component, the study will consist of up to a 28-day screening period, a treatment period of up to approximately 168 days, a 30-day safety follow-up visit, and long-term follow up. Long-term follow up will conclude with the final analysis.In the phase 2 component, enrolled subjects will receive blinatumomab monotherapy. In the phase 3 component, enrolled subjects will be randomized in a 1:1 ratio to blinatumomab or IC chemotherapy.

In March 2019, decision made to not proceed with phase 3.

03

Conditions studied

  • B-Cell Non Hodgkin Lymphoma

Keywords

  • Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma
  • Blinatumomab
  • Leukemia
  • Standard of Care
  • SOC
  • Cancer
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven aggressive B-cell Non-Hodgkin Lymphoma (B-NHL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), follicular lymphoma Grade 3B, PMBCL, T-cell rich B-cell lymphoma, or DLBCL that represents transformation of indolent non-Hodgkin's Lymphoma (NHL), (including follicular, marginal zone, and lymphoplasmacytoid lymphoma) excluding chronic lymphocytic leukemia or Hodgkin Lymphoma. The following histologies are not eligible:

    • Lymphoblastic lymphoma
    • Burkitt lymphoma
    • Mantle cell lymphoma Any histologies not specifically mentioned must be discussed with medical monitor.
  • (no prior CR/CMR) or relapsed (prior CMR) following front line treatment of standard multiagent chemotherapy containing an anthracycline AND an approved anti-CD20 agent. For subjects with refractory disease and who have received radiotherapy, PET positivity should be demonstrated no less than 6 weeks after the last dose of radiotherapy
  • Biopsy proven confirmation of relapsed disease.
  • Received a minimum of 2 cycles of standard of care platinum-based chemotherapy in the S1 setting and had a response of progressive metabolic disease (PMD), no metabolic response (NMR), partial metabolic response (PMR) as centrally assessed by PET-/ CT scan or received at least 1 cycle of S1 chemotherapy and had evidence of PMD as centrally assessed. A pre-salvage scan is required to be submitted to the central reader if a subject had only 1 cycle of pre-salvage chemotherapy.
  • Radiographically with a demarcated nodal lesion at least 1.5 cm in its largest dimension or a target extranodal lesion at least 1.0 cm in its largest dimension
  • performance status less than or equal to 2
  • Intention to proceed to high dose chemotherapy (HDT) and hematopoietic stem cell transplant (HSCT)
  • Laboratory parameters:

Hematology:

  • (ANC) ≥ 1.0 x 10\^9/L
  • ≥ 75 x 10\^9/L

Chemistry:

  • ≥ 50 mL/min
  • (AST)/alanine aminotransferase (ALT) \< 3X (ULN)
  • Total (TBL) \< 2x ULN (unless Gilbert's disease or if liver involvement with lymphoma)

Exclusion criteria

Exclusion Criteria:

  • CMR following S1 chemotherapy
  • Treatment within 30 days prior to randomization with another device or drug study (ies).
  • Prior anti-CD19-directed therapies
  • Prior HDT with HSCT
  • Prior allogeneic HSCT
  • central nervous system (CNS) pathology such as epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
  • Evidence of CNS involvement by NHL
  • Known infection with or chronic infection with virus (hepatitis B surface antigen positive) or virus (anti hepatitis C virus positive)
  • History of other than B-NHL within the past 3 years with the exception of:

    • Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment
    • Adequately treated non-melanoma skin cancer or lentigo maligna
    • Adequately treated cervical carcinoma in situ
    • Adequately treated breast ductal carcinoma in situ
    • Prostatic intraepithelial neoplasia without evidence of prostate cancer
    • Adequately treated urothelial papillary non-invasive carcinoma or carcinoma in situ
  • Known sensitivity to immunoglobulins or any of the components to be administered during dosing.
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required procedures.
  • History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
  • Female subjects who are pregnant or breastfeeding or planning to become pregnant or breastfeed, or of unwilling to use an effective method of while receiving, and for an additional 48 hours after the last dose of blinatumomab.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Blinatumomab is administered as a continuous intravenous infusion (CIVI). A single cycle of blinatumomab is continuous infusion with step dosing of 9 µg/day x 7 days, 28 µg/day x 7 days, and 112 µg/days until the end of the cycle.

    Drug: Blinatumomab

Interventions

  • Blinatumomab monotherapy

    Also known as: AMG 103, Blincyto

06

What researchers measure

Primary outcomes

  1. Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR)

    Complete metabolic response (CMR) was determined by central radiographic assessment of positron emission tomography and computed tomography (PET/CT) scans using the Lugano Classification.

    Time frame: Up to 12 weeks after first dose of blinatumomab

  2. Phase 3: Number of Participants Who Achieved Complete Metabolic Response (CMR)

    Complete metabolic response (CMR) was determined by central radiographic assessment of positron emission tomography and computed tomography (PET/CT) scans using the Lugano Classification.

    Time frame: Up to 12 weeks after first dose of study treatment

Secondary outcomes

  1. Phase 2: Overall Survival (OS)

    OS was defined as the time from the date of randomization until death due to any cause. OS was calculated using Kaplan-Meier estimates.

    Time frame: From randomization until the end of study, up to 30 months

  2. Phase 2: Objective Response Rate (ORR)

    ORR is inclusive of all participants who achieved CMR or those who achieved partial metabolic response (PMR), as determined by central radiographic assessment of PET/CT scans using the Lugano Classification.

    Time frame: Up to 12 weeks after first dose of blinatumomab

  3. Phase 2: Progression Free Survival (PFS)

    PFS was defined as the time from start of treatment with blinatumomab until the date of diagnosis of progression of lymphoma, or date of death, whichever is earliest. PFS was estimated using Kaplan-Meier method.

    Time frame: From first dose of blinatumomab until the end of study, up to 30 months

  4. Phase 2: Duration of Response (DOR)

    DOR was calculated only for participants who achieve a response (CMR or PMR). The duration was calculated from the date a response, CMR or PMR, was first achieved until the earliest date of a disease assessment indicating disease progression or death, whichever occured first. DOR was estimated using Kaplan-Meier method.

    Time frame: From first dose of blinatumomab up to 12 weeks

  5. Phase 2: Percentage of Participants Who Experienced Successful Mobilization

    Successful mobilization rate was defined as the percentage of participants who initiated mobilization while in remission and without any other anti-tumor therapy where the mobilization procedure had an outcome of 'Successful'. Successful mobilization was dictated by institutional standards and defined when the target cell dose was no less than 2 x 10\^6 CD34+ cells/kg.

    Time frame: From first dose of blinatumomab until the end of study, up to 30 months

  6. Phase 2: Percentage of Participants Who Had Allogeneic or Autologous Post-baseline Hematopoietic Stem Cell Transplant (HSCT)

    The percentage of responders per investigator's review (participants who achieved either CMR or PMR during the treatment) who have undergone allogeneic (allo) HSCT or autologous (auto) HSCT while in remission and without any other anti-cancer treatment.

    Time frame: From baseline HSCT until the end of study, up to 30 months

  7. Phase 2: Cumulative Incidence Function Estimate of 100-day Mortality After HSCT Presented as Percentage of Participants That Died Not Due to Relapse, With Relapse and Death Due to Relapse as Competing Events

    Non-relapse mortality rate at 100 days after HSCT was calculated as the percentage of participants who died not due to relapse. Only participants who achieved a response per investigator's review and underwent autoHSCT are included.

    Time frame: 100 days after HSCT

  8. Phase 2: Blinatumomab Steady State Concentrations (Css)

    Pharmacokinetic (PK) parameters were estimated by non compartmental analysis. The Css of blinatumomab was summarized as the observed concentrations collected after at least 24 hours after the start of continuous IV infusion or start of dose step, where appropriate.

    Time frame: Pre-dose on Day 1, and post-dose on Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

  9. Phase 2: Blinatumomab Clearance (CL)

    Serum blinatumomab CL was calculated as CL=R0/Css,DN; where R0 is the infusion rate (μg/hr) and Css,DN is the dose normalized average Css. For the CL calculation, the Css,DN was normalized to the 112 μg/day dose in which the value of dose in units of μg/hr was used for the infusion rate.

    Time frame: Pre-dose on Day 1, and post-dose on Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

  10. Phase 2: Half-life of Blinatumomab

    Time frame: Pre-dose on Day 1, and Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

  11. Phase 2: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

    Treatment-emergent adverse events were events with an onset after the administration of the first dose of blinatumomab. TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE). Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated.

    Time frame: From first dose of blinatumomab until 30 days after last dose. The maximum treatment duration for blinatumomab was 114 days

  12. Phase 3: Objective Response Rate (ORR)

    Time frame: Up to 12 weeks after first dose of study treatment

  13. Phase 3: Progression Free Survival (PFS)

    Time frame: From first dose of study treatment until the end of study, up to 30 months

  14. Phase 3: Duration of Response (DOR)

    Time frame: From first dose of study treatment up to 12 weeks

  15. Phase 3: Percentage of Participants Who Experienced Successful Mobilization

    Time frame: From baseline until the end of study, up to 30 months

  16. Phase 3: Percentage of Participants Who Had Allogeneic or Autologous Post-baseline Hematopoietic Stem Cell Transplant (HSCT)

    Time frame: From baseline HSCT until the end of study, up to 30 months

  17. Phase 3: Percentage of Participants Who Died Within 100 Days After Hematopoietic Stem Cell Transplantation (HSCT) That Was Not Due to Relapse

    Time frame: 100 days after HSCT

  18. Phase 3: Change From Baseline in Patient Reported Clinical Outcome Assessments Quality of Life (QOLCOA) Scores

    Time frame: Up to 30 days after last dose after study treatment

  19. Phase 3: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

    Time frame: From first dose of study treatment until 30 days after last dose

  20. Phase 3: Serum Blinatumomab Steady State Concentration (Css)

    Time frame: 24 hours after first dose of blinatumomab

  21. Phase 3: Blinatumomab Clearance (CL)

    Time frame: Pre-dose on Day 1, and Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

  22. Phase 3: Half-life of Blinatumomab

    Time frame: Pre-dose on Day 1, and Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

07

Results

Posted Jan 13, 2021
Limitations and caveats
Phase 3 part of the study was not initiated after Phase 2 data was reviewed. No participants were screened or enrolled for Phase 3.

Participant flow

Participants were enrolled at 19 research centers in Australia, Belgium, Italy, Spain, the United Kingdom, and the United States from 23 January 2017 to 15 January 2018.

Phase 2
Participant flow — Phase 2
MilestonePhase 2: BlinatumomabPhase 3: BlinatumomabPhase 3: Investigator's Choice (IC) Chemotherapy
Started4100
Started cycle 14100
Started optional cycle 2400
Completed1300
Not completed2800
Withdrew: Withdrawal by subject300
Withdrew: Lost to follow-up100
Withdrew: Death2400
Phase 3
Participant flow — Phase 3
MilestonePhase 2: BlinatumomabPhase 3: BlinatumomabPhase 3: Investigator's Choice (IC) Chemotherapy
Started000
Completed000
Not completed000

Outcome measures

PrimaryPhase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR)

Complete metabolic response (CMR) was determined by central radiographic assessment of positron emission tomography and computed tomography (PET/CT) scans using the Lugano Classification.

Time frame:
Up to 12 weeks after first dose of blinatumomab
Reported as:
Number · Percentage of participants
Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR)
Percentage of participantsPhase 2: Blinatumomab
Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR)22.0 (10.6 to 37.6)
PrimaryPhase 3: Number of Participants Who Achieved Complete Metabolic Response (CMR)

Complete metabolic response (CMR) was determined by central radiographic assessment of positron emission tomography and computed tomography (PET/CT) scans using the Lugano Classification.

Time frame:
Up to 12 weeks after first dose of study treatment

No measurements were reported for this outcome.

SecondaryPhase 2: Overall Survival (OS)

OS was defined as the time from the date of randomization until death due to any cause. OS was calculated using Kaplan-Meier estimates.

Time frame:
From randomization until the end of study, up to 30 months
Reported as:
Median · Months
Phase 2: Overall Survival (OS)
MonthsPhase 2: Blinatumomab
Phase 2: Overall Survival (OS)11.2 (5.9 to NA)
SecondaryPhase 2: Objective Response Rate (ORR)

ORR is inclusive of all participants who achieved CMR or those who achieved partial metabolic response (PMR), as determined by central radiographic assessment of PET/CT scans using the Lugano Classification.

Time frame:
Up to 12 weeks after first dose of blinatumomab
Reported as:
Number · Percentage of participants
Phase 2: Objective Response Rate (ORR)
Percentage of participantsPhase 2: Blinatumomab
Phase 2: Objective Response Rate (ORR)36.6 (22.1 to 53.1)
SecondaryPhase 2: Progression Free Survival (PFS)

PFS was defined as the time from start of treatment with blinatumomab until the date of diagnosis of progression of lymphoma, or date of death, whichever is earliest. PFS was estimated using Kaplan-Meier method.

Time frame:
From first dose of blinatumomab until the end of study, up to 30 months
Reported as:
Median · Months
Phase 2: Progression Free Survival (PFS)
MonthsPhase 2: Blinatumomab
Phase 2: Progression Free Survival (PFS)2.9 (2.3 to 5.3)
SecondaryPhase 2: Duration of Response (DOR)

DOR was calculated only for participants who achieve a response (CMR or PMR). The duration was calculated from the date a response, CMR or PMR, was first achieved until the earliest date of a disease assessment indicating disease progression or death, whichever occured first. DOR was estimated using Kaplan-Meier method.

Time frame:
From first dose of blinatumomab up to 12 weeks
Reported as:
Median · Months
Phase 2: Duration of Response (DOR)
MonthsPhase 2: Blinatumomab
Phase 2: Duration of Response (DOR)6.1 (2.5 to 10.7)
SecondaryPhase 2: Percentage of Participants Who Experienced Successful Mobilization

Successful mobilization rate was defined as the percentage of participants who initiated mobilization while in remission and without any other anti-tumor therapy where the mobilization procedure had an outcome of 'Successful'. Successful mobilization was dictated by institutional standards and defined when the target cell dose was no less than 2 x 10\^6 CD34+ cells/kg.

Time frame:
From first dose of blinatumomab until the end of study, up to 30 months
Reported as:
Number · Percentage of participants
Phase 2: Percentage of Participants Who Experienced Successful Mobilization
Percentage of participantsPhase 2: Blinatumomab
Phase 2: Percentage of Participants Who Experienced Successful Mobilization40.0 (16.3 to 67.7)
SecondaryPhase 2: Percentage of Participants Who Had Allogeneic or Autologous Post-baseline Hematopoietic Stem Cell Transplant (HSCT)

The percentage of responders per investigator's review (participants who achieved either CMR or PMR during the treatment) who have undergone allogeneic (allo) HSCT or autologous (auto) HSCT while in remission and without any other anti-cancer treatment.

Time frame:
From baseline HSCT until the end of study, up to 30 months
Reported as:
Number · Percentage of participants
Phase 2: Percentage of Participants Who Had Allogeneic or Autologous Post-baseline Hematopoietic Stem Cell Transplant (HSCT)
Percentage of participantsPhase 2: Blinatumomab
AlloHSCT6.7 (0.2 to 31.9)
AutoHSCT53.3 (26.6 to 78.7)
SecondaryPhase 2: Cumulative Incidence Function Estimate of 100-day Mortality After HSCT Presented as Percentage of Participants That Died Not Due to Relapse, With Relapse and Death Due to Relapse as Competing Events

Non-relapse mortality rate at 100 days after HSCT was calculated as the percentage of participants who died not due to relapse. Only participants who achieved a response per investigator's review and underwent autoHSCT are included.

Time frame:
100 days after HSCT
Reported as:
Number · Percentage of participants
Phase 2: Cumulative Incidence Function Estimate of 100-day Mortality After HSCT Presented as Percentage of Participants That Died Not Due to Relapse, With Relapse and Death Due to Relapse as Competing Events
Percentage of participantsPhase 2: Blinatumomab
Phase 2: Cumulative Incidence Function Estimate of 100-day Mortality After HSCT Presented as Percentage of Participants That Died Not Due to Relapse, With Relapse and Death Due to Relapse as Competing Events0.0 (0.0 to 0.0)
SecondaryPhase 2: Blinatumomab Steady State Concentrations (Css)

Pharmacokinetic (PK) parameters were estimated by non compartmental analysis. The Css of blinatumomab was summarized as the observed concentrations collected after at least 24 hours after the start of continuous IV infusion or start of dose step, where appropriate.

Time frame:
Pre-dose on Day 1, and post-dose on Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)
Reported as:
Mean · Picograms/millilter (pg/mL)
Phase 2: Blinatumomab Steady State Concentrations (Css)
Picograms/millilter (pg/mL)Phase 2: Blinatumomab 9 µg/DayPhase 2: Blinatumomab 28 µg/DayPhase 2: Blinatumomab 112 µg/Day
Phase 2: Blinatumomab Steady State Concentrations (Css)249 ± 200804 ± 5133470 ± 3700
SecondaryPhase 2: Blinatumomab Clearance (CL)

Serum blinatumomab CL was calculated as CL=R0/Css,DN; where R0 is the infusion rate (μg/hr) and Css,DN is the dose normalized average Css. For the CL calculation, the Css,DN was normalized to the 112 μg/day dose in which the value of dose in units of μg/hr was used for the infusion rate.

Time frame:
Pre-dose on Day 1, and post-dose on Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)
Reported as:
Mean · Liter/hour (L/hr)
Phase 2: Blinatumomab Clearance (CL)
Liter/hour (L/hr)Phase 2: Blinatumomab
Phase 2: Blinatumomab Clearance (CL)1.78 ± 0.747
SecondaryPhase 2: Half-life of Blinatumomab
Time frame:
Pre-dose on Day 1, and Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

No measurements were reported for this outcome.

SecondaryPhase 2: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)

Treatment-emergent adverse events were events with an onset after the administration of the first dose of blinatumomab. TEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE). Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL. Grade 4 Life-threatening consequences; urgent interventions indicated.

Time frame:
From first dose of blinatumomab until 30 days after last dose. The maximum treatment duration for blinatumomab was 114 days
Reported as:
Count of participants · Participants
Phase 2: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
ParticipantsPhase 2: Blinatumomab
TEAEs41
Grade ≥ 2 TEAEs37
Grade ≥ 3 TEAEs29
Grade ≥ 4 TEAEs12
Serious TEAEs20
TEAEs leading to discontinuation of blinatumomab7
TEAEs leading to interruption of blinatumomab13
Fatal TEAEs7
SecondaryPhase 3: Objective Response Rate (ORR)
Time frame:
Up to 12 weeks after first dose of study treatment

No measurements were reported for this outcome.

SecondaryPhase 3: Progression Free Survival (PFS)
Time frame:
From first dose of study treatment until the end of study, up to 30 months

No measurements were reported for this outcome.

SecondaryPhase 3: Duration of Response (DOR)
Time frame:
From first dose of study treatment up to 12 weeks

No measurements were reported for this outcome.

SecondaryPhase 3: Percentage of Participants Who Experienced Successful Mobilization
Time frame:
From baseline until the end of study, up to 30 months

No measurements were reported for this outcome.

SecondaryPhase 3: Percentage of Participants Who Had Allogeneic or Autologous Post-baseline Hematopoietic Stem Cell Transplant (HSCT)
Time frame:
From baseline HSCT until the end of study, up to 30 months

No measurements were reported for this outcome.

SecondaryPhase 3: Percentage of Participants Who Died Within 100 Days After Hematopoietic Stem Cell Transplantation (HSCT) That Was Not Due to Relapse
Time frame:
100 days after HSCT

No measurements were reported for this outcome.

SecondaryPhase 3: Change From Baseline in Patient Reported Clinical Outcome Assessments Quality of Life (QOLCOA) Scores
Time frame:
Up to 30 days after last dose after study treatment

No measurements were reported for this outcome.

SecondaryPhase 3: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
Time frame:
From first dose of study treatment until 30 days after last dose

No measurements were reported for this outcome.

SecondaryPhase 3: Serum Blinatumomab Steady State Concentration (Css)
Time frame:
24 hours after first dose of blinatumomab

No measurements were reported for this outcome.

SecondaryPhase 3: Blinatumomab Clearance (CL)
Time frame:
Pre-dose on Day 1, and Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

No measurements were reported for this outcome.

SecondaryPhase 3: Half-life of Blinatumomab
Time frame:
Pre-dose on Day 1, and Days 2, 9 and 16 of Cycle 1 (Cycle 1 was 70 days)

No measurements were reported for this outcome.

Adverse events

Collected over From first dose of blinatumomab until 30 days after last dose. The maximum treatment duration for blinatumomab was 114 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 2: Blinatumomab25/41 (61%)20/41 (48.8%)29/41 (70.7%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPhase 2: Blinatumomab
Confusional statePsychiatric disorders3/41
SepsisInfections and infestations2/41
Diffuse large B-cell lymphoma refractoryNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/41
Atrial fibrillationCardiac disorders1/41
Abdominal painGastrointestinal disorders1/41
Pancreatitis acuteGastrointestinal disorders1/41
PyrexiaGeneral disorders1/41
BacteraemiaInfections and infestations1/41
Lower respiratory tract infectionInfections and infestations1/41
PneumoniaInfections and infestations1/41
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPhase 2: Blinatumomab
HeadacheNervous system disorders10/41
PyrexiaGeneral disorders9/41
Back painMusculoskeletal and connective tissue disorders9/41
TremorNervous system disorders9/41
Oedema peripheralGeneral disorders8/41
AnaemiaBlood and lymphatic system disorders6/41
ConstipationGastrointestinal disorders6/41
NauseaGastrointestinal disorders6/41
NeutropeniaBlood and lymphatic system disorders5/41
HypomagnesaemiaMetabolism and nutrition disorders5/41

Baseline characteristics

Full Analysis Set (FAS): All participants who received blinatumomab.

Age, Continuous
Age, Continuous(Years)Phase 2: Blinatumomab
Mean54.7 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2: Blinatumomab
Female13
Male28
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 2: Blinatumomab
Hispanic or Latino6
Not Hispanic or Latino35
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 2: Blinatumomab
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White38
More than one race0
Unknown or Not Reported1
08

Study locations

31 sites
  • Research Site
    Duarte, California 91010, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Oklahoma City, Oklahoma 73104, United States
  • Research Site
    Greenville, South Carolina 29607, United States
  • Research Site
    St Leonards, New South Wales 2065, Australia
  • Research Site
    Herston, Queensland 4029, Australia
  • Research Site
    Melbourne, Victoria 3004, Australia
  • Research Site
    Parkville, Victoria 3052, Australia
  • Research Site
    Murdoch, Western Australia 6150, Australia
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Bergamo, 24127, Italy
  • Research Site
    Firenze, 50134, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Palermo, 90146, Italy
  • Research Site
    Pisa, 56100, Italy
  • Research Site
    Roma, 00161, Italy
  • Research Site
    Udine, 33100, Italy
  • Research Site
    San Juan, 00918, Puerto Rico
  • Research Site
    Cordoba, Andalucía 14004, Spain
  • Research Site
    Valladolid, Castilla León 47012, Spain
  • Research Site
    Barcelona, Cataluña 08025, Spain
  • Research Site
    Santiago de Compostela, Galicia 15706, Spain
  • Research Site
    Madrid, 28034, Spain
  • Research Site
    Madrid, 28041, Spain
  • Research Site
    Murcia, 30008, Spain
  • Research Site
    Bristol, BS2 8ED, United Kingdom
  • Research Site
    Nottingham, NG5 1PB, United Kingdom
  • Research Site
    Sheffield, S10 2JF, United Kingdom
09

References and documents

Publications

  • Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness CL, Zhang A, Jung AS, Cohan D, Franklin JL. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2020 Sep;61(9):2103-2112. doi: 10.1080/10428194.2020.1759055. Epub 2020 Jun 16. PubMed 32546071 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Mar 2020, 37 months.

Results were first posted in Jan 2021, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2016
First posted
Sep 21, 2016
StartActual
Jan 23, 2017
Primary completionActual
Mar 12, 2020
CompletionActual
Mar 12, 2020
Results first posted
Jan 13, 2021
Last update
Jan 13, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02910063
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 21, 2016
Start date
Jan 23, 2017
Primary completion
Mar 12, 2020
Completion
Mar 12, 2020
Results posted
Jan 13, 2021
Last update
Jan 13, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion